Противоопухолевая и антиметастатическая активность siРНК, РНКазы А и ДНКазы I — препаратов, способных специфически и неспецифически вызывать деградацию нуклеиновых кислот
Диссертация
Мы не обнаружили влияния ДНКазы I в диапазоне доз 0.02 — 2.3 мг/кг на рост первичной опухоли ни на одной из исследованных опухолевых моделей, что может быть связано с отсутствием её проникновения внутрь клеток. Сравнительно недавно было показано, что внеклеточные ДНК могут быть связаны с поверхностью клеток и циркулировать в кровотоке. Повышение уровня внеклеточной ДНК в плазме крови было… Читать ещё >
Список литературы
- Ставровская А. Клеточные механизмы множественной лекарственной устойчивости опухолевых клеток // Биохимия. 2000. — Т. 65, № 1. — Р. 95−106.
- Gottesman М. М., Fojo Т., Bates S. Е. Multidrug resistance in cancer: role of ATP-dependent transporters // Nat. Rev. Cancer. 2002. -V. 2, № 1. — P. 48−58.
- Ambudkar S. V., Kimchi-Sarfaty C., Sauna Z. E., Gottesman M. M. P-glycoprotein: from genomics to mechanism // Oncogene. 2003. — V. 22, № 47. — P. 7468−7485.
- Dive C. Avoidance of apoptosis as a mechanism of drug resistance // J. Intern. Med. -1997.-№ 740.-P. 139−145.
- Frenkel G. D., Caffrey P. B, A prevention strategy for circumventing drug resistance in cancer chemotherapy//Curr. Pharm. Des. -2001. -V. 7, № 16. P. 1595−1614.
- Germann Ui A., Harding M, W. Chemosensitizers to overcome and prevent multidrug resistance? // J. Natl. Cancer Inst. 1995. -V. 87, № 21. — P. 1573−1575.
- Bishop J. M. Retroviruses and cancer genes //Adv. Cancer Res. 1982. — № 37. — P. 132.
- Campbell S. b, Khosravi-Far R., Rossman K. L., Clark G. J., Der C. J. Increasing complexity of Ras signaling // Oncogene. 1998. — V. 17, № 11. — P. 1395−413.
- Rowley J. D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining // Nature. 1973. — V. 243, № 5405. — P. 290−293.
- Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis // Am. J. Pathol. 1995. — V. 146, № 5. — P. 1029−1039.
- Bernhard E. J., Muschel R. J., Hughes E. N. Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells // Cancer Res. 1990. — V. 50, № 13.-P. 3872−3877.
- Garzon R., Fabbri M., Cimmino A., Calin G. A., Croce С. M. MicroRNA expression and function in cancer//Trends Mol. Med. -2006. -V. 12, № 12.-- P. 580−587.
- Wong T. S" Liu X. В., Wong B. Y" Ng R. W., Yuen A. P., Wei W. I. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue // Clin. Cancer Res. 2008. — V. 14, № 9. — P. 2588−2592.
- Steeg P. S. Tumor metastasis: mechanistic insights and clinical challenges // Nature. -2006. -V. 12, № 8. P. 895−904.
- Garcia-Olmo D., Garcia-Olmo D. C., Ontanon J., Martinez E. Horizontal transfer of DNA and the «genometastasis hypothesis» // Blood. 2000. — V. 95, № 2. — P. 724−735.
- Kotchetkov R., Cinatl J., Krivtchik A. A., Vogel J. U., Matousek J., Pouckova P., Kornhuber В., Sohwabe D., Cinatl J. Selective activity of BS-RNase against anaplastic thyroid cancer // Anticancer Res. 2001. — V. 21, № 2A. — P. 1035−1042.
- Soucek J., Pouckova P., Matousek J., Stockbauer P., Dostal J., Zadinova M. Antitumor action of bovine seminal ribonuclease // Neoplasma. 1996. — V. 43, № 5. — P. 335−340.
- Lee I., Lee Y. H., Mikulski S. M., Lee J., Covone K., Shogen K. Tumoricidal effects of onconase on various tumors//J. Surg. Oncol. 2000.-V. 73, № 3. — P. 164−171.
- Costanzi J., Sidransky D., Navon A., Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase // Cancer Invest. 2005. — V. 23, № 7. — P. 643−650.
- Roth J. S. Ribonuclease activity and cancer: a review // Cancer Res. 1963. — № 23. -P. 657−666.
- Ledoux L. Action of ribonuclease on two solid tumours in vivo // Nature. 1955. — V. 176, № 4470. — P. 36−37.
- Ledoux L. Action of ribonuclease on certain ascites tumours // Nature. 1955. — V. 175, № 4449. — P. 258−259.
- Манойлов С. E., Орлова Е. И., Полосова Р. Г. Влияние рибонуклеазы на рост опухоли (в эксперименте) // Вопросы онкологии. 1966. — Т. 12, № 1. — С. 64−69.
- De Lamirande G. Action of deoxyribonuclease and ribonuclease on the growth of Ehrlich ascites carcinoma in mice // Nature. 1961. -V. 192. — P. 52−54.
- Tokita K., Sugihara S., Hiraoka Т., Miyauchi Y., Kambara Т., Yamamoto T. Effects of serine protease and deoxyribonuclease on intravascular tumor cell arrest in rat blood-borne lung metastasis // Invasion Metastasis. 1995. -V. 15, № 1−2. — P. 46−59.
- Belikova A. M., Zarytova V. F., Grineva N. I. Synthesis of ribonucleosides and diribonucleotide phosphates containing 2-chloro ethylamine and nitrogen mustard residues // Tetrahedron Letters. 1967. — .№ 37. — P. 3557−3562.
- Гринёва H. И., Карпова Г. Г. Комплементарно-адресное алкилирование рибосомной РНК алкилирующими производными олигонуклеотидов // Молекулярная биология. -1974.-Т. 8.-С. 832−844.
- Zamecnik P. C., Stephenson M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide // Proc. Natl. Acad. Sci. USA.- 1978. V. 75, № 1. — P. 280−284.
- Lee L. K., Roth C. M. Antisense technology in molecular and cellular bioengineering / L. K. Lee, C. M. Roth // Curr. Opin. Biotechnol. 2003. — V. 14, № 5. — P. 505−511.
- Helene C., Toulme J. J. Specific regulation of gene expression by antisense, sense and antigene nucleic acids // Biochim. Biophys. Acta. 1990. -V. 1049, № 2. — P. 99−125.
- Jason T. L., Koropatnick J., Berg R. W. Toxicology of antisense therapeutics II Toxicol. Appl. Pharmacol. 2004. — V. 201, № 1. — P. 66−83.
- Kurreck J. Antisense technologies. Improvement through novel chemical modifications // Eur. J. Biochem. 2003. — V. 270, № 8. — P, 1628−1644.
- Pirollo K. F., Rait A., Sleer L. S., Chang E. H. Antisense therapeutics: from theory to clinical practice // Pharmacol. Ther. 2003. -V. 99, № 1. — P. 55−77.
- Stahel R. A., Zangemeister-Wittke U. Antisense oligonucleotides for cancer therapy-an overview // Lung Cancer. 2003. -V. 41. — P. 81−88.
- Tafech A., Bassett T., Sparanese D., Lee C. H. Destroying RNA as a therapeutic approach / A. Tafech, T. Bassett, D. Sparanese, C. H. Lee // Curr. Med. Chem. 2006. — V. 13, № 8.-P, 863−881.
- Zamaratski E., Pradeepkumar P. I., Chattopadhyaya J. A critical survey of the structure-function of the antisense oligo/RNA heteroduplex as substrate for RNase H // J. Biochem. Biophys. Methods. 2001. -V. 48, № 3. — P. 189−208.
- Nielsen P. E., Egholm M., Berg R. H., Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide // Science. 1991. — V. 254, № 5037 — P. 1497−100.
- Larsen H. J., Bentin T., Nielsen P. E. Antisense properties of peptide nucleic acid //
- Biochim. Biophys. Acta. 1999. -V. 1489, № 1. — P. 159−166.
- Elayadi A. N., Corey D. R. Application of PNA and LNA oligomers to chemotherapy // Curr. Opin. Investig. Drugs. 2001. — V. 2, № 4. — P. 558−561.
- Gryznov S. M., Lloyd D. H., Chen J. K., Schultz R. G., DeDionisio L. A., Ratmeyer L., Wilson W. D. Oligonucleotide N3'→P5' phosphoramidates // Proc. Natl. Acad. Sci. U S A. -1995. -V. 92, № 13. P. 5798−5802.
- Koshkin A. A., Wengel J. Synthesis of Novel 2', 3'-Linked Bicyclic Thymine Ribonucleosides // J. Org. Chem. 1998. -V. 63, № 8. — P. 2778−2781.
- Obika S., Morio K., Hari Y., Imanishi Y. Preparation and properties of 2', 5'-linked oligonucleotide analogues containing 3'-0,4'-C-methyleneribonucleosides // Bioorg. Med. Chem. Lett. 1999. -V. 9, № 4. — P. 515−518.
- Heasman J. Morpholino oligos: making sense of antisense? // Dev. Biol. 2002. — V. 243, № 2.-P. 209−214.
- Nasevicius A., Ekker S. C. Effective targeted gene 'knockdown' in zebrafish // Nat. Genet. 2000. — V. 26, № 2. — P. 216−220.
- Fire A., Xu S., Montgomery M. K., Kostas S. A., Driver S. E., Mello C. C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans II Nature. -1998.-V. 391, № 6669.-P. 806−811.
- Downward J. RNA interference // Brit .Med. J. 2004. — V. 328, № 7450. — P. 1245−1248.
- Lingel A., Izaurralde E. RNAi: finding the elusive endonuclease // RNA. 2004. — V. 10, № 11. — P. 1675−1679.
- Leung R. K., Whittaker P. A. RNA interference: from gene silencing to gene-specific therapeutics // Pharmacol. Ther. 2005. — V. 107, № 2. — P. 222−239.
- Rand T. A., Ginalski K., Grishin N. V., Wang X. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity // Proc. Natl. Acad. Sci. U S A. 2004. — V. 101, № 40. — P. 14 385−14 389.
- Hannon G. J., Rossi J. J. Unlocking the potential of the human genome with RNA interference // Nature. 2004. — V. 431, № 7006. — P. 371−378.
- Kruger K., Grabowski P. J., Zaug A. J., Sands J., Gottschling D. E., Cech T. R. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena// Cell. -1982. -V. 31, № 1.-P. 147−157.
- Bagheri S., Kashani-Sabet M. Ribozymes in the age of molecular therapeutics // Curr. Mol. Med. 2004. — V. 4, № 5. — P. 489−506.
- Schubert S., Kurreck J. Ribozyme- and deoxyribozyme-strategies for medical applications // Curr. Drug Targets. 2004. — V. 5, № 8. — P. 667−681.
- Uhlenbeck O. C. A small catalytic oligoribonucleotide // Nature. 1987. — V. 328, № 6131.-P. 596−600.
- Haseloff J., Gerlach W. L. Simple RNA enzymes with new and highly specific endoribonuclease activities // Nature. 1988. -V. 334, № 6183. — P. 585−591.
- Kore A. R., Vaish N. K., Kutzke U., Eckstein F. Sequence specificity of the hammerhead ribozyme revisited- the NHH rule // Nucleic Acids Res. 1998. — V. 26, № 18. — P. 41 164 120.
- Ferre-D'Amare A. R. The hairpin ribozyme // Biopolymers. 2004. — V. 73, № 1. — P. 7178.
- Hampel A., R. Tritz. RNA catalytic properties of the minimum (-)sTRSV sequence // Biochemistry. 1989. -V. 28, № 12. — P. 4929−4933.
- Santoro S. W., Joyce G. F. A general purpose RNA-cleaving DNA enzyme // Proc. Natl. Acad. Sci. U S A. 1997. — V. 94, № 9. — P. 4262−4266.
- Kurreck J., Bieber В., Jahnel R., Erdmann V. Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I // J. Bio. I Chem. 2002. — V. 277, № 9. — P. 7099−7107.
- Копнин Б. П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза // Биохиия. 2000. — Т. 65, № 1. — С. 533.
- Barbacid M. ras genes //Annu. Rev. Biochem. 1987. — V. 56. — P. 779−827.
- Топе T., Kashani-Sabet M., Funato T., Shitara T., Yoshida E., Kashfian В. I., Horng M., Fodstadt O., Scanlon K. J. Suppression of EJ cells tumorigenicity // In Vivo. 1993. — V. 7, № 6A.-P. 471−476.
- Kashani-Sabet M., Funato T., Топе T., Jiao L., Wang W., Yoshida E., Kashfinn В. I., Shitara T., Wu A. M., Moreno J. G. Reversal of the malignant phenotype by an anti-ras ribozyme //Antisense Res. Dev. 1992. -V. 2, № 1. — P. 3−15.
- Ohta Y., Kijima H., Ohkawa T., Kashani-Sabet M., Scanlon K. J. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells // Nucleic Acids Res. 1996. — V. 24, № 5. — P. 938−942.
- Ohta Y., Kijima H., Kashani-Sabet M., Scanlon K. J. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes // J. Invest. Dermatol. 1996. — V. 106, № 2. — P. 275−280.
- Jaken S. Protein kinase С isozymes and substrates // Curr. Opin. Cell Biol. 1996. — V. 8, № 2. — P. 168−173.
- Deacon E. M., Pongracz J., Griffiths G., Lord J. M. Isoenzymes of protein kinase C: differential involvement in apoptosis and pathogenesis // Mol. Pathol. 1997. -V. 50, № 3. -P. 124−131.
- Blaschuk O., Burdzy K., Fritz I. B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid // J. Biol. Chem. 1983. — V. 258, № 12.-P. 7714−7720.
- Rosenberg M. E., Silkensen J. Clusterin: physiologic and pathophysiologic considerations // Int. J. Biochem. Cell Biol. 1995. -V. 27, № 7. — P. 633−645.
- Humphreys D. T., Carver J. A., Easterbrook-Smith S. B., Wilson M. R. Clusterin has chaperone-like activity similar to that of small heat shock proteins // J. Biol. Chem. 1999. -V. 274, № 11. — P. 6875−6881.
- Zellweger T., Miyake H., July L. V., Akbari M., Kiyama S., Gleave M. E. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin // Neoplasia. 2001. — V. 3, № 4. — P. 360−367.
- Blakesley V. A., Stannard B. S" Kalebic T" Helman L. J., LeRoith D. Role of the IGF-I receptor in mutagenesis and tumor promotion // J. Endocrinol. 1997. — V. 152, № 3. — P. 339−344.
- Guo Y. S., Jin G. F., Houston C. W., Thompson J. C., Townsend C. M. Jr. Insulin-like growth factor-l promotes multidrug resistance in MCLM colon cancer cells // J. Cell Physiol. -1998. -V. 175, № 2. P. 141−148.
- Singleton J. R., Dixit V. M., Feldman E. L. Type I insulin-like growth factor receptor activation regulates apoptotic proteins // J. Biol. Chem. 1996. — V. 271, № 50. — P. 3 179 131 794.
- Resnicoff M., Coppola D., Sell C., Rubin R., Ferrone S., Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor // Cancer Res. 1994. — V. 54, № 18. — P. 4848−4850.
- Tsujimoto Y., Cossman J., Jaffe E., Croce C. M. Involvement of the bcl-2 gene in human follicular lymphoma // Science. 1985. -V. 228, № 4706. — P. 1440−1443.
- Melanoma Study Group // J. Clin. Oncol. 2006. — V. 24, № 29. — P. 4738−4745.
- Altieri D. C. The molecular basis and potential role of survivin in cancer diagnosis and therapy // Trends Mol. Med. 2001. — V. 7, № 12. — P. 542−547.
- Altieri D. C., Marchisio P. C. Survivin apoptosis: an interloper between cell death and cell proliferation in cancer// Lab. Invest. 1999. -V. 79, № 11. — P. 1327−1333.
- Li F., Ambrosini G., Chu E. Y., Plescia J., Tognin S., Marchisio P. C., Altieri D. C. Control of apoptosis and mitotic spindle checkpoint by surviving // Nature. 1998. -V. 396, № 6711.- P. 580−584.
- Xia C., Xu Z., Yuan X., Uematsu K., You L., Li K., Li L., McCormick F., Jablons D. M. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides // Mol. Cancer Ther. 2002. — V. 1, № 9. — P. 687−694.
- Du Z. X., Zhang H. Y., Gao da X., Wang H. Q., Li Y. J., Liu G. L. Antisurvivin oligonucleotides inhibit growth and induce apoptosis in human medullary thyroid carcinoma cells // Exp. Mol. Med. 2006. — V. 38, № 3. — P. 230−240.
- Pennati M., Colella G., Folini M., Citti L., Daidone M. G., Zaffaroni N. Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis // J. Clin. Invest. 2002. — V. 109, № 2. — P. 285−286.
- Pennati M., Binda M., Colella G., Folini M" Citti L., Villa R., Daidone M. G., Zaffaroni N. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression // J. Invest. Dermatol. 2003. -V. 120, № 4. — P. 648−654.
- Choi K. S., Lee T. H., Jung M. H. Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells // Cancer Gene Ther.- 2003. V. 10, № 2. — P. 87−95.
- Lugo T. G., Pendergast A. M., Muller A. J., Witte O. N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products // Science. 1990. -V. 247, № 4946. -P. 1079−1082.
- Kuwabara T., Warashina M., Tanabe T., Tani K., Asano S., Taira K. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo // Mol. Cell. 1998. -V. 2, № 5. — P. 617−627.
- Wohlbold L., van der Kuip H., Miething C., Vornlocher H. P., Knabbe C., Duyster J., Aulitzky W. E. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571) // Blood. 2003. -V. 102, № 6. — P. 2236−2239.
- Daum G., Eisenmann-Tappe I., Fries H. W., Troppmair J., Rapp U. R. The ins and outs of Raf kinases //Trends Biochem. Sci. 1994. -V. 19, № 11. — R 474−480.
- Mayo M. W., Baldwin A. S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance // Biochim. Biophys. Acta. 2000. — V. 1470, № 2. — P. M55−62.
- Downward J. How BAD phosphorylation is good for survival // Nat. Cell Biol. 1999. -V. 1, № 2.-P. E33−5.
- Bos J. L. ras oncogenes in human cancer: a review // Cancer Res. 1989. — V. 49, № 17. — P. 4682−4689.
- Gao Z., Gao Z., Fields J. Z., Boman B. M. Tumor-specific expression of anti-mdrl ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells // Int. J. Cancer. 1999. — V. 82, № 3. — P. 346−352.
- Tew K. D. Glutathione-associated enzymes in anticancer drug resistance // Cancer Res. 1994. — V. 54. № 16. — P. 4313−4320.
- Szyf M. DNA methylation and cancer therapy // Drug Resist. Updat. 2003. — V. 6, № 6.-P. 341−353.
- Adams R. L., McKay E. L., Craig L. M., Burdon R. H. Methylation of mosquito DNA // Biochim. Biophys. Acta. 1979. -V. 563, № 1. — P. 72−81.
- Kautiainen T. L., Jones P. A. DNA methyltransferase levels in tumorigenic and nontumorigenic cells in culture //J. Biol. Chem. 1986. -V. 261, № 4. — P. 1594−1598.
- Wu J., Issa J. P., Herman J., Bassett D. E. Jr., Nelkin B. D., Baylin S. B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells // Proc. Natl. Acad. Sci. USA.- 1993. -V. 90, № 19. P. 8891−8895.
- Strathdee G., MacKean M. J., Illand M., Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer // Oncogene. -1999.-V. 18, № 14.-P. 2335−2341.
- Winquist E., Knox J., Ayoub J. P., Wood L., Wainman N., Reid G. K., Pearce L., Shah A.,
- Bryan T. M., Cech T. R. Telomerase and the maintenance of chromosome ends // Curr. Opin. Cell Biol. 1999. — V. 11, № 3. — P. 318−324.
- Artandi S. E., DePinho R. A. A critical role for telomeres in suppressing and facilitating carcinogenesis // Curr. Opin. Genet. Dev. 2000. — V. 10, № 1. — P. 39−46.
- Pitts A. E., Corey D. R. Inhibition of human telomerase by 2-O-methyl-RNA// Proc. Natl. Acad. Sci. USA.- 1998. -V. 95, № 20. P. 11 549−11 554.
- Kondo S., Kondo Y., Li G., Silverman R. H., Cowell J. K. Targeted therapy of human malignant glioma in a mouse model by 2−5A antisense directed against telomerase RNA // Oncogene. 1998. -V. 16, № 25. — P. 3323−3330.
- Engstrom Y., Eriksson S., Jildevik I., Skog S., Thelander L., Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits//J. Biol. Chem. 1985. -V. 260, № 16. — P. 9114−9116.
- Fan H., Villegas C., Huang A., Wright J. A. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation // Cancer Res. 1998. -V. 58, № 8. — P. 1650−1653.
- Folkman J. Tumor angiogenesis: therapeutic implications // N. Engl. J. Med. 1971. — V. 285, № 21.-P. 1182−1186.
- Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family // Cardiovasc. Res. 2001. — V. 49, № 3. — P. 568−581.
- Poltorak Z., Cohen T., Sivan R., Kandelis Y., Spira G., Vlodavsky I., Keshet E., Neufeld G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix//J. Biol. Chem. 1997. -V. 272, № 11. — P. 7151−7158.
- Petrova T. V., Makinen T., Alitalo K. Signaling via vascular endothelial growth factor receptors // Exp. Cell Res. 1999. -V. 253, № 1. — P. 117−130.
- Forster Y., Meye A., Krause S., Schwenzer B. Antisense-mediated VEGF suppression in bladder and breast cancer cells // Cancer Lett. 2004. — V. 212, № 1. — P. 95−103.
- Zhang L., Yang N., Mohamed-Hadley A., Rubin S. C., Coukos G. Vector-based RNAi, anovel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer // Biochem. Biophys. Res. Commun. 2003. -V. 303. № 4. — R 1169−1178.
- Ferrara N., Heinsohn H., Walder C. E., Bunting S., Thomas G. R. The regulation of blood vessel growth by vascular endothelial growth factor // Ann. N Y Acad. Sci. 1995. — V. 752. № 246−256.
- Stern D. F., Heffernan P. A., Weinberg R. A. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity // Mol. Cell Biol. 1986. — V. 6. № 5. — P. 1729−1740.
- Gusterson B. A. Identification and interpretation of epidermal growth factor and c-erbB-2 overexpression // Eur. J. Cancer. 1992. -V. 28. № 1. — P. 263−267.
- Lui V. W., He Y., Huang L. Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma // Mol. Ther. -2001. -V. 3. № 2. P. 169−177.
- De Benedetti A., Graff J. R. elF-4E expression and its role in malignancies and metastase // Oncogene. 2004. — V. 23. № 18. — P. 3189−3199.
- Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L. W., Sonenberg N. elF4E--from translation to transformation // Oncogene. 2004. — V. 23. № 18. — P. 3172−3179.
- Gingras A. C" Kennedy S. G., O’Leary M. A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt (PKB) signaling pathway // Genes Dev. 1998. — V. 12. № 4. — P. 502−513.
- Czubayko F., Schulte A. M., Berchem G. J., Wellstein A. Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin // Proc. Natl. Acad. Sci. USA.- 1996. -V. 93. № 25. P. 14 753−14 758.
- Morris S. W., Kirstein M. N., Valentine M. B., Dittmer K. G., Shapiro D. N., Saltman D.1., Look A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma //Science. 1994. -V. 263. № 5151. — P. 1281−1284.
- Powers C., Aigner A., Stoica G. E., McDonnell K., Wellstein A. Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth // J. Biol. Chem. -2002.-V. 277. № 16.-P. 14 153−14 158.
- Ochieng J., Fridman R., Nangia-Makker P., Kleiner D. E., Liotta L. A., Stetler-Stevenson W. G., Raz A. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9 // Biochemistry. 1994. -V. 33. № 47. — P. 14 109−14 114.
- Sehgal G., Hua J., Bernhard E. J., Sehgal I., Thompson T. C., Muschel R. J. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma //Am. J. Pathol. 1998. -V. 152. № 2. — P. 591−596.
- Gospodarowicz D., Ferrara N., Schweigerer L., Neufeld G. Structural characterization and biological functions of fibroblast growth factor // Endocr. Rev. 1987. — V. 8. № 2. — P. 95−114.
- Czubayko F., Smith R. V., Chung H. C., Wellstein A. Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors // J. Biol. Chem. 1994. -V. 269. № 45. — P. 28 243−28 248.
- Okamoto T., Tanaka Y., Kan M., Sakamoto A., Takada K., Sato J. D. Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells // In Vitro Cell Dev. Biol. Anim. 1996. — V. 32. № 2. — P. 69−71.
- Aigner A., Renneberg H., Bojunga J., Apel J., Nelson P. S., Czubayko F. Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo // Oncogene. 2002. -V. 21. № 37. — P. 5733−5742.
- Khachigian L. M., Collins T. Early growth response factor 1: a pleiotropic mediator of inducible gene expression // J. Mol. Med. 1998. -V. 76. № 9. — P. 613−616.
- Huang R. P., Fan Y., de Belle I., Niemeyer C., Gottardis M. M., Mercola D., Adamson E. D. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation // Int. J. Cancer. 1997. -V. 72. № 1. — P. 102−109.
- Gill P. K., Gescher A., Gant T. W. Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes alpha and theta // Eur. J. Biochem. 2001. -V. 268. № 15.-P. 4151−4157.
- Tsutsumi K., Kasaoka T., Park H. M., Nishiyama H., Nakajima M., Honda T. Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase // Int. J. Oncol. 2008. — V. 33. № 1. — P. 215−224.
- Bouchard C., Staller P., Eilers M. Control of cell proliferation by Myc //Trends Cell Biol. 1998. -V. 8. № 5. — P. 202−206.
- Liang Z" Yoon Y., Votaw J., Goodman M. M., Williams L" Shim H. Silencing of CXCR4 blocks breast cancer metastasis // Cancer Res. 2005. — V. 65. № 3. — P. 967−971.
- Monia B. P., Johnston J. F., Ecker D. J., Zounes M. A., Lima W. F., Freier S. M. Selective inhibition of mutant Ha -ras mRNA expression by antisense oligonucleotides // J. Biol. Chem.1992. -V. 267. № 28. P. 19 954−19 962.
- Liao Y., Tang Z. Y., Liu K. D., Ye S. L., Huang Z. Apoptosis of human BEL-7402 hepatocellular carcinoma cells released by antisense H-ras DNA~in vitro and in vivo studies // J. Cancer Res. Clin. Oncol. 1997. — V. 123. № 1. — P. 25−33.
- Yang G., Thompson J. A., Fang B., Liu J. Silencing of H-ras gene expression by retrovirus-mediated siRNA decreases transformation efficiency and tumorgrowth in a model of human ovarian cancer // Oncogene. 2003. — V. 22. № 36. P. 5694−5701.
- Brummelkamp T. R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference // Cancer Cell. 2002. — V. 2. № 3. — P. 243−247.
- Zhang Z., Jiang G., Yang F., Wang J. Knockdown of mutant K-ras expression by adenovirus-mediated siRNA inhibits the in vitro and in vivo growth of lung cancer cells // Cancer Biol. Ther. 2006. — V. 5. № 11. — P. 1481−1486.
- Kijima H., Yamazaki H., Nakamura M., Scanlon K. J., Osamura R. Y., Ueyama Y. Ribozyme against mutant K-ras mRNA suppresses tumor growth of pancreatic cancer // Int. J. Oncol. 2004. — V. 24. № 3. — P. 559−564.
- Watson P. H., Pon R. T., Shiu R. P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer // Cancer Res. 1991. — V. 51. № 15. — P. 3996−4000.
- Hudziak R. M., Summerton J., Weller D. D., Iversen P. L. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc //
- Antisense Nucleic Acid Drug Dev. 2000. — V. 10. № 3. — P. 163−176.
- Cheng J., Luo J., Zhang X., Hu J., Hui H., Wang C., Stern A. Inhibition of cell proliferation in HCC-9204 hepatoma cells by a c-myc specific ribozyme // Cancer Gene Ther. 2000. — V. 7. № 3. — P. 407−412.
- Kabilova T. O., Chernolovskaya E. L., Vladimirova A. V., Vlassov V. V. Silencing of c-myc expression in tumor cells by siRNA // Nucleosides Nucleotides Nucleic Acids. 2004. -V. 23. № 6−7. — P. 867−872.
- Kabilova T. O., Chernolovskaya E. L., Vladimirova A. V., Vlassov V. V. Inhibition of human carcinoma and neuroblastoma cell proliferation by anti-c-myc siRNA // Oligonucleotides. 2006. -V. 16. № 1. — P. 15−25.
- Shen L., Zhang C., Ambrus J. L., Wang J. H. Silencing of human c-myc oncogene expression by poly-DNP-RNA // Oligonucleotides. 2005. — V. 15. № 1. — P. 23−35.
- Wang Y. H. Y" Liu S., Zhang G., Zhou C. Q" Zhu H. X., Zhou X. B" Quan L. P., Bai J. F" Xu N. Z. Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo // Breast Cancer Res. 2005. — V. 7. № 2. — P. 220−228.
- Leirdal M., Sioud M. Ribozyme inhibition of the protein kinase C alpha triggers apoptosis in glioma cells // Br J Cancer. 1999. — V. 80. № 10. — P. 1558−1564.
- Kitada S., Miyashita T., Tanaka S., Reed J. C. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs //Antisense Res. Dev. 1993. — V. 3. № 2. — P. 157−169.
- Fu G. F., Lin X. H., Han Q. W., Fan Y. R., Xu Y. F., Guo D., Xu G. X., Hou Y. Y. RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo // Cancer Biol. Ther. 2005. — V. 4. № 8. — P. 822−829.
- Cotter F. E., Johnson P., Hall P., Pocock C., al Mahdi N" Cowell J. K., Morgan G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model // Oncogene. 1994. -V. 9. № 10. — P. 3049−3055.
- Ocker M., Neureiter D., Lueders M., Zopf S., Ganslmayer M., Hahn E. G., Herold C., Schuppan D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcI-2 in pancreatic cancer // Gut. 2005. -V. 54. № 9. — P. 1298−1308.
- Monia B. P., Johnston J. F., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase // Nat. Med. 1996. — V. 2, № 6. — P. 668−675.
- Monia B. P. First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies //Anticancer Drug Des. 1997. — V. 12. № 5. — P. 327 339.
- Lou T. F., Gray C. W., Gray D. M. The reduction of Raf-1 protein by phosphorothioate ODNs and siRNAs targeted to the same two mRNA sequences // Oligonucleotides. 2003. -V. 13. № 5.-P. 313−324.
- Duxbury M. S., Ito H., Zinner M. J., Ashley S. W., Whang E. E. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine // Oncogene. 2004. — V. 23. № 8. — P. 1539−1548.
- Zhang L., Gasper W. J., Stass S. A., loffe O. B., Davis M. A., Mixson A. J. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2 // Cancer Res. 2002. — V. 62. № 19. — P. 5463−5469.
- Shi W., Siemann D. W. Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approach //Anticancer Res. 2004. — V. 24. № 1. — P. 213−218.
- Kim W. J., Chang C. W., Lee M., Kim S. W. Efficient siRNA delivery using water soluble lipopolymer for anti-angiogenic gene therapy // J. Control. Release. 2007. — V. 118. № 3. -P. 357−363.
- Roh H., Hirose С. В., Boswell С. В., Pippin J. A., Drebin J. A. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents// Surgery. 1999. -V. 126. № 2. — P. 413−421.
- Sun H. Z., Wu S. F., Tu Z. H. Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity // Cell Res. 2001. — V. 11. № 2. — P. 107 115.
- Takamori K., Kubo Т., Zhelev Z., Rumiana В., Ohba H., Doi K., Fujii M. Suppression of bcr/abl chimeric gene by conjugate DNA enzymes in human cells // Nucleic Acids Symp. Ser. (Oxf). 2005. — V. 49. — P. 333−334.
- Bertram J., Palfner K., Killian M., Brysch W., Schlingensiepen К. H., Hiddemann W., Kneba M. Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes //Anticancer Drugs. 1995. -V. 6. № 1. — P. 124−134.
- Ren Y., Zhan X., Wei D., Liu J. In vitro reversal MDR of human carcinoma cell line by an antisense oligodeoxynucleotide-doxorubicin conjugate // Biomed. Pharmacother. 2004. — V. 58. № 9. — P. 520−526.
- Wang H., Chen X. P., Qiu F. Z. Overcoming multi-drug resistance by anti-MDR1 ribozyme // World J. Gastroenterol. 2003. -V. 9. № 7. — P. 1444−1449.
- Logashenko Е. В., Vladimirova А. V., Repkova М. N., Venyaminova A. G., Chernolovskaya Е. L., Vlassov V. V. Silencing of MDR 1 gene in cancer cells by siRNA // Nucleosides Nucleotides Nucleic Acids. -2004. -V. 23. № 6−7. P. 861−866.
- Nieth C., PriebschA., Stege A., Lage H. Modulation of the classical multidrug resistance
- MDR) phenotype by RNA interference (RNAi) // FEBS Lett. 2003. — V. 545. № 2−3. — P. 144−150.
- Duan Z" Brakora K. A., Seiden M. V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells // Mol. Cancer Ther. 2004. — V. 3. № 7. — P. 833−838.
- Hua J., Muschel R. J. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system // Cancer Res. 1996. — V. 56. N9 22. — P. 5279−5284.
- Sanceau J., Truchet S., Bauvois B. Matrix metalIoproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing’s sarcoma cells // J. Biol. Chem.- 2003. V. 278. № 38. — P. 36 537−36 546.
- Czubayko F., Liaudet-Coopman E. D., Aigner A., Tuveson A. T., Berchem G. J., Wellstein A. A secreted FGF-binding protein can serve as the angiogenic switch in human cancer // Nat. Med. 1997. — V. 3. № 10. — P. 1137−1140.
- Lapteva N., Yang A. G., Sanders D. E" Strube R. W., Chen S. Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo // Cancer Gene Ther. 2005. -V. 12. № 1. — P. 84−89.
- Chen Y., Stamatoyannopoulos G., Song C. Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro // Cancer Res. 2003. — V. 63. № 16. — P. 4801−4804.
- Ilinskaya O., Decker K., Koschinski A., Dreyer F., Repp H. Bacillus intermedius ribonuclease as inhibitor of cell proliferation and membrane current // Toxicology. 2001. — V. 156. № 2−3.-P. 101−107.
- Sevcik J., Urbanikova L., Leland P. A., Raines R. T. X-ray structure of two crystalline forms of a streptomycete ribonuclease with cytotoxic activity // J. Biol. Chem. 2002. — V. 277. № 49. — P. 47 325−47 330.
- Arnold U., Ulbrich-Hofmann R. Natural and engineered ribonucleases as potential cancer therapeutics // Biotechnol. Lett. 2006. -V. 28. № 20. — P. 1615−1622.
- Haigis M. C., Raines R. T. Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway // J. Cell Sci. 2003. -V. 116. № 2. — P. 313−324.
- Mastronicola M. R., Piccoli R., D’Alessio G. Key extracellular and intracellular steps in the antitumor action of seminal ribonuclease // Eur. J. Biochem. 1995. — V. 230. № 1. — P. 242−249.
- Benito A., Ribo M., Vilanova M. On the track of antitumour ribonucleases // Mol. Biosyst. 2001. — V. 1. № 4. — P. 294−302.
- Grabarek J., Ardelt В., Du L., Darzynkiewicz Z. Activation of caspases and serine proteases during apoptosis induced by Onconase (Ranpirnase) // Exp. Cell Res. 2000. — V. 278. № 1. — P. 61−71.
- Ни С. C., Tang С. H., Wang J. J. Caspase activation in response to cytotoxic Rana catesbeiana ribonuclease in MCF-7 cells // FEBS Lett. 2001. -V. 503. № 1. — P. 65−68.
- Wu Y. N" Mikulski S. M., Ardelt W., Ryback S. M., Youle R. J. A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity // J. Biol. Chem. 1993. — V. 268. № 14. -P. 10 686−10 693.
- Ardelt В., Ardelt W., Darzynkiewicz Z. Cytotoxic ribonucleases and RNA interference (RNAi). Cell Cycle. 2003. — V. 2. № 1. — P. 22−24.
- Johnson R. J., Chao T. Y., Lavis L. D., Raines R. T. Cytotoxic ribonucleases: the dichotomy of Coulombic forces // Biochemistry. 2007. — V. 46. № 36. — P. 10 308−10 316.
- Leland P. A,. Schultz L. W., Kim В. M., Raines R. T. Ribonuclease A variant with potent cytotoxic activity // Proc. Natl. Acad. Sci. USA. 1998. -V. 95. № 18. — P. 10 407−10 412.
- Naddeo M., Vitagliano L., Russo A., Gotte G., D’Alessio G., Sorrentino S. Interactions of the cytotoxic RNase A dimers with the cytosolic ribonuclease inhibitor // FEBS Lett. 2005. -V. 579. № 12. — P. 2663−2668.
- Sorrentino S., Naddeo M., Russo A., D’Alessio G. Degradation of double-stranded RNA by human pancreatic ribonuclease: crucial role of noncatalytic basic amino acid residues // Biochemistry. 2003. -V. 42. № 34. — P. 10 182−10 190.
- Blaszczyk J., Gan J., Tropea J. E., Court D. L., Waugh D. S., Ji X. Noncatalytic assembly of ribonuclease III with double-stranded RNA II Structure. 2004. — V. 12. № 3. -P. 457−466.
- Kojima K. Molecular aspects of the plasma membrane in tumor cells // Nagoya J. Med. Sci. 1993. -V. 56. № 1−4. — P. 1−18.
- Ran S., Downes A., Thorpe P. E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels // Cancer Res. -2002. -V. 62. № 21. P. 6132−6140.
- Ильинская О. H., Макаров А. А. Почему рибонуклеазы вызывают гибель раковыхклеток// Молекулярная биолгоия. 2005. — Т. 39. № 1. — С. 3−13.
- Bracale A., Spalletti-Cernia D., Mastronicola М., Castaldi F., Mannucci R., Nitsch L., D’Alessio G. Essential stations in the intracellular pathway of cytotoxic bovine seminal ribonuclease // Biochem. J. 2002. — V. 362. № 3. — P. 553−560.
- Sills R. C., Boorman G. A., Neal J. E., Hong H. L., Devereux T. R. Mutations in ras genes in experimental tumours of rodents // IARC Sci. Publ. 1999. — V. 146. — P. 55−86.
- Scharovsky O. G., Rozados V. R., Gervasoni S. I., Matar P. Inhibition of ras oncogene: a novel approach to antineoplastic therapy // J. Biomed. Sci. 2000. — V. 7. № 4. — P. 292 298.
- Ilinskaya O. N., Dreyer F., Mitkevich V. A., Shaw K. L., Pace C. N" Makarov A. A. Changing the net charge from negative to positive makes ribonuclease Sa cytotoxic // Protein Sci. 2002. — V. 11. № 10. — P. 2522−2525.
- Ilinskaya O. N. Koschinski A., Mitkevich V. A., Repp H., Dreyer F., Pace C. N., Makarov A. A. Cytotoxicity of RNases is increased by cationization and counteracted by K (Ca) channels // Biochem. Biophys. Res. Commun. 2004. -V. 314. № 2. — P. 550−554.
- Di Gaetano S., D’Alessio G., Piccoli R. Second generation antitumour human RNase: significance of its structural and functional features for the mechanism of antitumour action // Biochem. J.-2001,-V. 358. № 1.-P. 241−247.
- Adinolfi B. S., Cafaro V., D’Alessio G., Di Donato A. Full antitumor action of recombinant seminal ribonuclease depends on the removal of its N-terminal methionine // Biochem. Biophys. Res. Commun. 1995. -V. 213. № 2. — P. 525−532.
- Bracale A., Castaldi F., Nitsch L., D’Alessio G. A role for the intersubunit disulfides of seminal RNase in the mechanism of its antitumor action // Eur. J. Biochem. 2003. -V. 270. № 9.-P.-1980−1987.
- Kim J. S., Soucek J., Matousek J., Raines R. T. Structural basis for the biological activity of bovin seminal ribonuclease // J. Biol. Chem. 1995. -V. 270. № 18. — P. 10 525−10 530.
- Matousek J. Ribonucleases and their antitumor activity // Сотр. Biochem. Physiol. С Toxicol. Pharmacol. 2001. — V. 129. № 3. — P. 175−191.
- Kim J. S., Soucek J., Matousek J., Raines R. T. Mechanism of ribonuclease cytotoxicity // J. Biol. Chem. 1995. — V. 270. № 52. — P. 31 097−31 102.
- Laccetti P., Spalletti-Cernia D., Portella G., De Corato P., D’Alessio G., Vecchio G. Seminal ribonuclease inhibits tumor growth and reduces the metastatic potential of Lewis lung carcinoma // Cancer Res. 1994. -V. 54. № 16. — P. 4253−4256.
- Lee I., Lee Y. H" Mikulski S. M" Shogen K. Effect of ONCONASE±tamoxifen on ASPC-1 human pancreatic tumors in nude mice // Adv. Exp. Med. Biol. 2003. — V. 530. — P. 187 196.
- Vogelzang N. J., Aklilu M., StadlerW. M" Dumas M. C., Mikulski S. M. A phase II trial of weekly intravenous ranpirnase (Onconase), a novel ribonuclease in patients with metastatic kidney cancer // Invest. New Drugs. -2001. -V. 19. № 3. P. 255−260.
- Herndon J. E., Green M. R., Chahinian A. P. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B//Chest. -1998.-V. 113. № 3. 723−731.
- Matousek J., Soucek J., Slavik T., Tomanek M., Lee J. E., Raines R. T. Comprehensive comparison of the cytotoxic activities of onconase and bovine seminal ribonuclease // Comp. Biochem. Physiol. C Toxicol. Pharmacol. 2003. -V. 136. № 4. — P. 343−356.
- Pouckova P., Skvor J., Gotte G" Vottariello F., Slavik J. T., Matousek J., Laurents D. V., Libonati M., Soucek J. Some biological actions of PEG-conjugated RNase A oligomers // Neoplasma. 2006. -V. 53. № 1. — P. 79−85.
- Di Donato A., Cafaro V., D’Alessio G. Ribonuclease A can be transformed into a dimeric ribonuclease with antitumor activity // J. Biol. Chem. 1994. — V. 269. № 26. — P. 1 739 417 396.
- Lee J. E., Raines R. T. Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoral activity // Biochemistry. 2003. — V. 42. № 39. — P. 1 144 311 450.
- Gaur D., Swaminathan S., Batra J. K. Interaction of human pancreatic ribonuclease with human ribonuclease inhibitor. Generation of inhibitor-resistant cytotoxic variants // J. Biol. Chem. 2001. — V. 276. № 27. — P. 24 978−24 984.
- Rutkoski T. J., Kurten E. L., Mitchell J. C., Raines R. T. Disruption of shape-complementarity markers to create cytotoxic variants of ribonuclease A // J. Mol. Biol. V. 354. № 1. — P. 41−54.
- Lee J. E., Raines R. T. Cytotoxicity of Bovine Seminal Ribonuclease: Monomer versus Dimer// Biochemistry. V. 44. № 48. — P. 15 760−15 767.
- Newton D. L., Xue Y., Boque L., Wlodawer A., Kung H. F., Rybak S. M. Expression andcharacterization of a cytotoxic human-frog chimeric ribonuciease: potential for cancer therapy // Protein Eng. 1997. — V. 10. № 4. — P. 463−470.
- Schein С. H. From housekeeper to microsurgeon: the diagnostic and therapeutic potential of ribonucleases // Nat. Biotechnol. 1997. -V. 15. № 6. — P. 529−536.
- Rybak S. M., Newton D. L. Natural and engineered cytotoxic ribonucleases: therapeutic potential // Exp. Cell Res. 1999. -V. 253. № 2. — P. 325−335.
- Krauss J., Arndt M. A., Vu B. K" Newton D. L" Seeber S" Rybak S. M. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein // Biochem. Biophys. Res. Commun. -2005. V. 331. № 2. — P. 595−602.
- De Lorenzo C., Arciello A., Cozzolino R., Palmer D. В., Laccetti P., Piccoli R., D’Alessio G. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas // Cancer Res. -V. 64. № 14. P. 4870−4874.
- Leich F., Koditz J., Ulbrich-Hofman R., Arnold U. Tandemization endows bovine pancreatic ribonuciease with cytotoxic activity // J. Mol. Biol. 2006. — V. 358. № 5. — P. 1305−1313.
- Gotte G., Bertoldi M., Libonati M. Structural versatility of bovine ribonuciease A. Distinct conformers of trimeric and tetrameric aggregates of the enzyme // Eur. J. Biochem. 1999. -V. 265. № 2. — P. 680−687.
- Matousek J., Gotte G., Pouckova P., Soucek J., Slavik Т., Vottariello F., Libonati M. Antitumor activity and other biological actions of oligomers of ribonuciease A // J. Biol. Chem. 2003. — V. 278. № 26. — P. 23 817−23 822.
- Vasandani V. M., Wu Y. N., Mikulski S. M., Youle R. J., Sung C. Molecular determinants in the plasma clearance and tissue distribution of ribonucleases of the ribonuciease A superfamily//Cancer Res. 1996.-V. 56. № 18. — P. 4180−4186.
- Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy // Mol. Aspects Med. 2007. — V. 28. № 1. — P. 4−41.
- Greco O., Dachs G. U. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives //J. Cell Physiol. -2001. -V. 187. № 1. P. 22−36.
- Dilber M. S., Smith C. I. Suicide genes and bystander killing: local and distant effects // Gene Ther. 1997. — V. 4. № 4. — P. 273−274.
- Xu G., McLeod H. L. Strategies for enzyme/prodrug cancer therapy // Clin. Cancer Res. — 2001. — V. 7. № 11.-P. 3314−3324.
- Fillat C., Carrio M., Cascante A., Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application // Curr. Gene Ther. 2003. — V. 3. № 1. — P. 13−26.
- Elion G. B. The biochemistry and mechanism of action of acyclovir // J. Antimicrob. Chemother. 1983. -V. 12. — P. 9−17.
- Short M. P., Choi B. C" Lee J. K., Malick A., Breakefield X. O., Martuza R. L. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line // J. Neurosci Res. 1990. — V. 27. № 3. — P. 427−439.
- Caruso M., Panis Y., Gagandeep S., Houssin D., Salzmann J. L., Klatzmann D. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene // Proc. Natl. Acad. Sci USA.- 1993. V. 90. № 15. — P. 7024−7028.
- O’Malley B. W. Jr., Chen S. H., Schwartz M. R., Woo S. L. Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model // Cancer Res. 1995. -V. 55. № 5. — P. 1080−1085.
- Mullen C. A., Kilstrup M., Blaese R. M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system // Proc. Natl. Acad. Sci USA. 1992. -V. 89. № 1. — P. 33−37.
- Anderson L. M., Krotz S., Weitzman S. A., Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach // Cancer Gene Ther. 2000. — V. 7. № 6. — P. 845−852.
- Tai C. K., Wang W. J., Chen T. C., Kasahara N. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma // Mol. Ther. 2005. — V. 12. № 5. — P. 842−851.
- Drabek D., Guy J., Craig R., Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954 // Gene Ther. 1997. -V. 4. № 2.-P. 93−100.
- Bridgewater J. A., Knox R. J., Pitts J. D., Collins M. K., Springer C. J. The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite // Hum. Gene Ther. 1997. -V. 8. № 6. — P. 709−717.
- Chen L., Waxman D. J., Chen D., Kufe D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene // Cancer Res. 1996. -V. 56. № 6. — P. 1331−1340.
- Salmons B., Lohr M., Gunzburg W. H. Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase l/ll clinical trial // J. Gastroenterol. 2003. — V. 38. — P. 78−84.
- Kinzler K. W., Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers // Nature. 1997. — V. 386. № 6627. — P. 761, 763.
- Fang B., Roth J. A. Tumor-suppressing gene therapy // Cancer Biol. Ther. 2003. — V. 2.-P. 115−21.
- Polyak K., Xia Y., Zweier J. L., Kinzler K. W., Vogelstein B. A model for p53-induced apoptosis // Nature. 1997. — V. 389. № 6648. — P. 300−305.
- Tanaka H., Arakawa H., Yamaguchi T., Shiraishi K., Fukuda S., Matsui K., Takei Y., Nakamura Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage // Nature. 2000. — V. 404. № 6773. — P. 42−49.
- Wei M. Q., Metharom P., Ellem K. A., Barth S. Search for «weapons of mass destruction» for cancer immuno/gene therapy comes of age // Cell. Mol. Immunol. — 2005. — V. 2. — P. 351−357.
- Roth J. A., Grammer S. F., Swisher S. G., Komaki R., Nemunaitis J., Merritt J., Fujiwara T., Meyn R. E. Jr. Gene therapy approaches for the management of non-small cell lung cancer // Semin. Oncol. 2001. — V. 28. № 4. — P. 50−56.
- Swisher S. G., Roth J. A., Carbone D. P. Genetic and immunologic therapies for lung cancer // Semin. Oncol. 2002. — V. 29. № 1. — P. 95−101.
- Pearson S., Jia H., Kandachi K. China approves first gene therapy // Nat. Biotechnol. -2004.-V. 22. № 1.-P. 3−4.
- Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers// Hum. Gene Ther. 2005. — V. 16. № 9. — P. 1016−1027.
- Ribas A., Butterfield L. H., Economou J. S. Genetic immunotherapy for cancer // Oncologist. 2000. -V. 5. № 2. — P. 87−98.
- Leng J., Zhang L., Yao H., Cao X. Antitumor effects of interleukin-18 gene-modified hepatocyte cell line on implanted liver carcinoma // Chin. Med. J. (Engl). 2003. -V. 116. № 10. — P. 1475−1479.
- Lebedeva I. V., Sarkar D" Su Z. Z., Gopalkrishnan R. V., Athar M" Randolph A., Valerie K., Dent P., Fisher P. B. Molecular target-based therapy of pancreatic cancer // Cancer Res. 2006. — V. 66. № 4. — P. 2403−2413.
- Hernandez-Alcoceba R., Sangro B., Prieto J. Gene therapy of liver cancer // World J. Gastroenterol. 2006. -V. 12. № 38. — P. 6085−6097.
- Trinchieri G., Pflanz S., Kastelein R. A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses // Immunity. 2003. — V. 19. № 5. — P. 641 -644.
- Sgadari С., Angiolillo A. L., Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10 // Blood. 1996. — V. 87. № 9. — P. 38 773 882.
- Hart D. N. Dendritic cells: unique leukocyte populations which control the primary immune response // Blood. 1997. -V. 90. № 9. — P. 3245−3287.
- Северин' E. С., Родина А. В. Проблемы и перспективы современной противоопухолевой терапии // Успехи биологической химии. 2006. — Т. 46. — С. 43−64.
- Massard G., Tongio М. М., Wihlm J. М., Morand G. The dendritic cell lineage: a ubiquitous antigen-presenting organization //Ann. Thorac. Surg. 1996. — V. 61. № 1. — P. 252−258.
- Peters J. H., Gieseler R., Thiele В., Steinbach F. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants // Immunol. Today. 1996. — V. 17. № 6. — P. 273 278.
- Austyn J. M. Dendritic cells // Curr. Opin. Hematol. 1998. -V. 5. № 1. — P. 3−15.
- Kikuchi T. Genetically modified dendritic cells for therapeutic immunity // Tohoku J. Exp. Med. 2006. — V. 208. № 1. — P. 1 -8.
- Ishida Т., Oyama Т., Carbone D. P., Gabrilovich D. I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors//J. Immunol. 1998.-V. 161. № 9. — P. 4842−4851.
- Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R" Burg G., Schadendorf
- D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells // Nat. Med. 1998. -V. 4. № 3. — P. 328−332.
- Lee W. C., Wang H. C., Hung C. F., Huang P. F., Lia C. R., Chen M. F. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial II J. Immunother. 2005. — V. 28. № 5. — P. 496−504.
- Butterfield L. H. Recent advances in immunotherapy for hepatocellular cancer // Swiss Med. Wkly. 2007. — V. 137. № 5−6. — P. 83−90.
- Nestle F. O. Dendritic cell vaccination for cancer therapy // Oncogene. 2000. — V. 19. № 56. — P. 6673−6679.
- Fong L., Brockstedt D., Benike C., Breen J. K., Strang G., Ruegg C. L., Engleman E. G. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy // J. Immunol. -2001. -V. 167. № 12. P. 7150−7156.
- Fong L., Brockstedt D., Benike C., Wu L., Engleman E. G. Dendritic cells injected via different routes induce immunity in cancer patients // J. Immunol. 2001. — V. 166. № 6. — P. 4254−4259.
- Кок Т., Wolters H., Bloks V. W" Havinga R" Jansen P.L., Staels В., Kuipers F. Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse // Gastroenterology. 2003. -V.124. № 1. P.160−171.
- Damha M. J., Ogilvie К. K. Oligoribonucleotide synthesis. The silyl-phosphoramidite method // Methods Mol. Biol. 1993. № 20. — P. 81−114.
- Каледин В. И., Николин В. П., Агеева Т. А. и др. Циклофосфамид-индуцированный апоптоз клеток мышиной лимфосаркомы в условиях in vivo // Вопр. онкологии. 2000. -Т. 46. № 5. Р. 588−593.
- Каледин В. И., Поляченко В. М. Новый перевиваемый штамм мышиной гепатомы («гепатома А») // Экспериментальные животные в медицинских исследованиях. 1974. Москва. — С. 50−52.
- Chattopadhyay N., Kher R., Godbole M. Inexpensive SDS/phenol method for RNA extraction from tissues // Biotechniques. 1993. — V.15. № 1. — P. 24−26.
- Tomayko M. M., Reynolds C. P. Determination of subcutaneous tumor size in athymic (nude) mice//Cancer Chemother. Pharmacol. 1989. -V. 24. № 3. P. 148−154.
- Silberklang M., Gillum A. M., RhajBhandary U. L. Use of in vitro 32P labeling in the-sequence analysis of nonradioactive tRNAs // Methods Enzymol. 1979. № 59. — P. 58 -109.
- Лактионов П. П., Тамкович С. Н., Симонов П. А., Рыкова Е. Ю., Власов В. В. Способ выделения дезоксирибонуклеиновой кислоты // 2004. Россия.
- Labarca C., Paigen K. A simple, rapid, and sensitive DNA assay procedure //Annal Biochem. 1980. -V. 102. № 2. P. 344 — 352.
- Boddy A.V., Yule S.M. Metabolism and pharmacokinetics of oxazaphosphorines // Clin. Pharmacokinet. 2000. — V. 38. № 4. — P. 291−304.
- Чумаков П. M. Функция р53: выбор между жизнью и смертью // Биохимия. 2000. -Т. 65. № 1.-С. 34−47.
- Akiyama S., Fojo A., Hanover J. A., Pastan I., Gottesman M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs // Somat. Cell Mol. Genet. 1985.-V. 11. № 2.-P. 117−126.
- Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs // J. Natl. Cancer Inst. 1993. — V. 85. № 8. — P. 632−639.
- Wachek V., Losert D., Gunsberg P., Vornlocher H. P., Hadwiger P., Geick A., Pehamberger H., Muuler M., Jansen B. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma // Oligonucleotides. 2003. -V. 13. № 5. — P. 393−400.
- Elbashir S.M., Harborth J., Lendeckel W" Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells // Nature. 2001. -V. 411. № 6836. — P. 494−498.
- Sakaeda Т., Nakamura Т., Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics//Biol. Pharm. Bull. -2002. V. 25. № 11.-P. 1391−1400.
- Лапик А. С., Губенко И. С., Корочкин Л. И., Салганик Р. И. Фармакологическая активность и токсичность нуклеаз // Фармакол. и токсикол. 1970. № 2. — С. 210−211.
- Antignani A., Naddeo М., Cubellis М. V., Russo A., D’Alessio G. Antitumor action of seminal ribonuclease, its dimeric structure, and its resistance to the cytosolic ribonuclease inhibitor // Biochemistry. 2001. — V. 40. № 12. — P. 3492−3496.
- Bretscher L. E., Abel R. L., Raines R. T. A ribonuclease A variant with low catalytic activity but high cytotoxicity // J. Biol. Chem. 2000. — V. 275. № 14. — P. 9893−9896.
- Salganik R. I., Martynova R. P., Matienko N. A., Ronichevskaya G. M. Effect of deoxyribonuclease on the course of lymphatic leukaemia in AKR mice // Nature. 1967. — V. 214. № 5083.-P. 100−102.
- Laktionov P. P., Tamkovich S. N., Rykova E. Y., Bryzgunova О. E., Starikov A. V., Kuznetsova N. P., Vlassov V. V. Cell-surface-bound nucleic Acids in blood of healthy donors and breast cancer patients //Ann. N YAcad. Sci. 2004. № 1022. — P. 221−227.
- Bremnes R. M., Sirera R., Camps C. Circulating tumor-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? // Lung Cancer. 2005. — V. 49. № 1. — P. 1−12.
- Tong Y., Lo Y. D. Diagnostic developments involving cell-free (circulating) nucleic acids // Clin. Chim. Acta. 2006. — V. 363. № 1−2. — P. 187−196.
- Combaret V., Audoynaud C., lacono I., Favrot M. C., Schell M., Bergeron C., Puisieux A. Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients // Cancer
- Res. 2002. — V. 62, № 13. — P. 3646−3648.
- Klink T. A., Raines R. T. Conformational stability is a determinant of ribonuclease A cytotoxicity // J. Biol. Chem. 2000. -V. 275. № 23. — P. 17 463−17 467.
- Semenov D. V., Baryakin D. N., Kamynina T. P., Kuligina E. V., Richter V. A. Fragments of noncoding RNA in plasma of human blood //Ann. N Y Acad. Sci. 2008. — V. 1137. — P. 130−134.
- Smith M. R., Newton D. L" Mikulski S. M., Rybak S. M. Cell cycle-related differences in susceptibility of NIH/3T3 cells to ribonucleases // Exp. Cell Res. 1999. — V. 247. № 1. — P. 220−232.